Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05723965
Other study ID # CE21235B
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2010
Est. completion date December 31, 2022

Study information

Verified date February 2023
Source Taichung Veterans General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigator retrospective collect cases during 2010-2021 diagnosed as rectal adenocarcinoma with high quality CT images. Local advanced rectal cancer cases were labeled as "disease". Nor were defined " normal". Using artificial intelligence CNN on jupyter notebook with open phyton code to train and develop models capable to recognizing local advanced rectal cancer. Modify the phyton code for better predict rate and help physician to quickly evaluate disease severity for fresh rectal cancer cases.


Description:

From 2010.10.1~2021.12.31, rectal cancer patients with cT3-4 lesion was included. Collect high quality CT images with DICOM files in tumor segment. cT1-2, low rectal lesions, non-CRC cases were not included. Non-contrast and artificial defect images were also excluded. CT images were labeled as" diseased " when CRM were threatened (<2mm). All images were labeled according to judgment of 2 specialist. The data were separated into 2 parts. One for AI model training and testing, another for external validation. The training testing dataset was achieved by deep learning neural network and evaluating model accuracy performance. Then the model was applied into external validation dataset for real-world testing, evaluating coherent rate between AI and the Dr. decision. Furthermore, to see the cancer survival outcomes according to AI model prediction results.


Recruitment information / eligibility

Status Completed
Enrollment 720
Est. completion date December 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 100 Years
Eligibility Inclusion Criteria: - clinical staging T3-4 with high quality CT images. Exclusion Criteria: - 1. not primary malignancy lesion - 2. not localizing rectum - 3. T1-2 lesion - 4. non contrast or poor quality images

Study Design


Related Conditions & MeSH terms


Intervention

Other:
As training material for deep learning model.
Using labeled images as training materials for artificial intelligence to develop object detecting model.
As materials for external validation for the buildup model.
Using the external validation set to evaluate prediction rate and survival outcome.

Locations

Country Name City State
Taiwan Taichung Verterans General Hospital Taichung

Sponsors (1)

Lead Sponsor Collaborator
Taichung Veterans General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary accuracy of artificial intelligence with experienced physician accuracy between artificial intelligence and experienced physician 1 week after images done.
Secondary real life survival outcome of diagnosis by artificial intelligence. real life survival outcome by artificial intelligence. 5 years after diagnosed
See also
  Status Clinical Trial Phase
Completed NCT05495308 - "Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Recruiting NCT04598984 - The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Active, not recruiting NCT04246684 - Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients Phase 3
Not yet recruiting NCT05830890 - Sentinel Lymph Node Biopsy in Rectal Cancer N/A
Active, not recruiting NCT04503694 - Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer Phase 2
Completed NCT02363374 - Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT03561142 - Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. Phase 2
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Recruiting NCT05148767 - UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer Phase 4
Recruiting NCT06254521 - The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer Phase 2
Completed NCT01325649 - Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma N/A
Recruiting NCT04970498 - Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Active, not recruiting NCT03840239 - TNT to Increase the Clinical Complete Response Rate for Distal LARC Phase 2
Active, not recruiting NCT03391843 - Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer Phase 2